Αποτελέσματα Αναζήτησης
The greater intensity of health care service use by cancer patients trigger increasing health care cost, resulting in a greater overall burden of cancer. It is estimated that the direct medical costs for cancer in the US in 2014 were $87.8 billion ( American Cancer Society, 2017 ).
6 Αυγ 2020 · England's National Institute for Health and Care Excellence (NICE) and the US’ Institute for Clinical and Economic Review (ICER) both conduct cost-effectiveness evaluations for new cancer drugs to help payers make drug coverage decisions. However, NICE and ICER assessments have been noted to reach different conclusions.
4 Οκτ 2024 · The USA spent $99 billion on orally administered and clinician-administered anticancer therapies (excluding supportive care) in 2023 and spending is projected to increase to $180 billion by 2028.
17 Οκτ 2018 · In our thorough review of recent studies describing total and OOP costs along the cancer care continuum, we observed that, depending on age and disease stage, the net cost to all payers of common cancers can be expected to be between $20,000 and $100,000 in the initial year after diagnosis and ≥$60,000 at the end of life.
The American Society of Clinical Oncology (ASCO) guidance statement on the cost of cancer care, published in 2009, makes a notable contribution to this discussion. 33 This statement argues that physicians have a societal responsibility to provide care that is evidence based to minimize waste. Importantly, it also notes that the individual ...
9 Μαρ 2021 · Cancer treatment is a significant driver of healthcare costs worldwide, however, the economic impact of treating patients with anti-neoplastic agents is poorly elucidated. We conducted a systematic review and meta-analysis to estimate the direct costs associated with administering intravenous chemotherapy in an outpatient setting.
5 Δεκ 2019 · This systematic review highlights findings from modern analyses of the cost effectiveness of breast cancer care. We found that targeting general populations for cancer control interventions has reasonable costs per QALY saved compared with doing nothing but that risk-targeted approaches lowered costs without major trade-offs in lives saved.
